Sanofi-Aventis to Acquire Genzyme (LAUREN UZDIENSKI @ HealthPointCapital)
After a long and very public negotiation, Genzyme has agreed to be acquired by Sanofi-Aventis for $74 per share, with the total deal valued at around $20.1 billion. The transaction represents a 48% increase over the close on July 2, before rumors began to circulate that Genzyme was an acquisition target, and about a 4.7x sales multiple.
In addition to the $74 in cash per share, shareholders may also receive an additional $14 a share based on milestone payments associated with multiple-sclerosis drug Lemtrada and producti...
